Literature DB >> 19686787

PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.

Lisa M Kaminskas1, Jagannath Kota, Victoria M McLeod, Brian D Kelly, Peter Karellas, Christopher Jh Porter.   

Abstract

Polylysine dendrimers have potential as highly flexible, biodegradable nanoparticular carriers that may also promote lymphatic transport. The current study was undertaken to determine the impact of PEGylation on the absorption and lymphatic transport of polylysine dendrimers modified by surface derivatisation with PEG (200, 570 or 2000Da) or 4-benzene sulphonate following SC or IV dosing. PEGylation led to the PEG(200) derived dendrimer being rapidly and completely absorbed into the blood after SC administration, however only 3% of the administered dose was recovered in pooled thoracic lymph over 30h. Increasing the PEG chain length led to a systematic decrease in absorption into the blood and an enhancement of the proportion recovered in the lymphatics (up to 29% over 30h). For the PEG(570) and PEG(2000) derived dendrimers, indirect access to the lymph via equilibration across the capillary beds also appeared to play a role in lymphatic targeting after both IV and SC dosing. In contrast, the anionic benzene sulphonate-capped dendrimer was not well absorbed from the SC injection site (26% bioavailability) into either the blood or the lymph. The data suggest that PEGylated poly-L-lysine dendrimers are well absorbed from SC injection sites and that the extent of lymphatic transport may be enhanced by increasing the size of the PEGylated dendrimer complex.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19686787     DOI: 10.1016/j.jconrel.2009.08.005

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  32 in total

Review 1.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

2.  A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep.

Authors:  Gemma M Ryan; Robert J Bischof; Perenlei Enkhbaatar; Victoria M McLeod; Linda J Chan; Seth A Jones; David J Owen; Christopher J H Porter; Lisa M Kaminskas
Journal:  Pharm Res       Date:  2015-10-20       Impact factor: 4.200

Review 3.  From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Authors:  Natalie L Trevaskis; Lisa M Kaminskas; Christopher J H Porter
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

4.  Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination.

Authors:  Sejin Son; Jutaek Nam; Ilia Zenkov; Lukasz J Ochyl; Yao Xu; Lindsay Scheetz; Jinjun Shi; Omid C Farokhzad; James J Moon
Journal:  Nano Lett       Date:  2020-02-10       Impact factor: 11.189

5.  Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery.

Authors:  Matthew T Haynes; Leaf Huang
Journal:  ACS Appl Mater Interfaces       Date:  2016-09-09       Impact factor: 9.229

6.  Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery.

Authors:  Susan N Thomas; Alex Schudel
Journal:  Curr Opin Chem Eng       Date:  2015-02-01       Impact factor: 5.163

Review 7.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

8.  Lymph node effective vascular permeability and chemotherapy uptake.

Authors:  Eelco F J Meijer; Cedric Blatter; Ivy X Chen; Echoe Bouta; Dennis Jones; Ethel R Pereira; Keehoon Jung; Benjamin J Vakoc; James W Baish; Timothy P Padera
Journal:  Microcirculation       Date:  2017-08       Impact factor: 2.628

9.  PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.

Authors:  Lisa M Kaminskas; David B Ascher; Victoria M McLeod; Marco J Herold; Caroline P Le; Erica K Sloan; Christopher J H Porter
Journal:  J Control Release       Date:  2013-03-15       Impact factor: 9.776

10.  Recent advances in targeted drug delivery approaches using dendritic polymers.

Authors:  Jason Bugno; Hao-jui Hsu; Seungpyo Hong
Journal:  Biomater Sci       Date:  2014-12-11       Impact factor: 6.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.